The present study evaluated clinically the effects of a probiotic on oral microbiota and glycemic control in T2 diabetic patients with periodontal disease. The study was designed as a prospective randomized, double-blind, placebo- controlled interventional study. At baseline and at the end of the 30 day- probiotic period, all clinical, microbiological, and biochemical measurements were tested. Colony counts of oral microbiota, blood fructosamine levels and CRP were the outcomes of the study.

Objectives: To investigate the effects of an oral probiotic use, containing 4 billion colony forming unit (CFU/g) Streptococcus Salivarius M18 strain (Dentoblis™), on the quantities of oral microbiota in saliva and metabolic markers of T2 diabetics such as fructosamine, C-reactive protein (CRP).

Materials and Methods: The trial was designed as a prospective randomized, double-blind, placebo- controlled interventional study. Participants were selected from type 2 diabetics with periodontitis and aged 30-65 years, who presented to the Diabetic Center in Istanbul. Totally 70 patients were randomly assigned to probiotic or placebo groups. At baseline and at the end of the 30 day-probiotic period, colony counts of oral microbiota and biochemical measurements of diabetes were assessed.

Inclusion Criteria:

• being diagnosed with T2 diabetes with <10% HbA1C for at least 6 months,
• 30-65 years old patients,
• high caries activity patients with Periodontal Disease Index (PDI) scores of 2, 3, 4 and 5,
• provision of written informed consent -

Exclusion Criteria:

• patients regularly using probiotics,
• patients on corticosteroid, non-steroid anti-inflammatory, antibiotic or antibacterial mouthwash therapy,
• patients with multi-organ deficiency such as liver or kidney failure,
• patients with Immunodeficiency syndrome or on immunosuppressive therapy,
• patients with heart valve prosthesis or central venous catheter,
• patients undergoing chronic or acute disease therapy such as cancer, arthritis, influenza, flu,
• legal incapability or mental incapacity to give consent.

All information will be available to share with other researchers

As of January 2022

No criteria

Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse, who was also responsible for keeping the codes and information confidential until after the statistical calculations. Statistical analysis were performed by a blind assessor.